Literature DB >> 17229636

Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma.

Luca Agnelli1, Silvio Bicciato, Sonia Fabris, Luca Baldini, Fortunato Morabito, Daniela Intini, Donata Verdelli, Andrea Callegaro, Francesco Bertoni, Giorgio Lambertenghi-Deliliers, Luigia Lombardi, Antonino Neri.   

Abstract

BACKGROUND AND OBJECTIVES: The chromosome 13 deletion (Delta13) is one of the most frequent chromosomal alterations in multiple myeloma (MM). Delta13 is associated with an unfavorable prognosis, although there is increasing agreement that its prognostic relevance must be related to the ploidy status and the presence of different chromosomal translocations. The aim of this study was to provide a comprehensive analysis of the transcriptional features of Delta13 in MM. DESIGN AND METHODS: Highly purified plasma cells from 80 newly diagnosed MM patients were characterized by means of fluorescence in situ hybridization (FISH) and high-density oligonucleotide microarray for gene expression profiling and chromosomal alterations.
RESULTS: We identified 67 differentially expressed genes in the patients with and without the chromosome 13 deletion, all of which were downregulated in the cases with Delta13: 44 mapped along the whole chromosome 13, seven on chromosome 11 and three on chromosome 19. Functional analyses of the selected genes indicated their involvement in protein biosynthesis, ubiquitination and transcriptional regulation. An integrative genomic approach based on regional analyses of the gene expression data identified distinct chromosomal regions whose global expression modulation could differentiate Delta13-positive cases, in particular the upregulation of 1q21-1q42 and the downregulation of 19p and almost the entire chromosome 11. FISH analyses confirmed the close relationship between Delta13-positivity and the presence of extra copies of 1q21-1q42 (p=6 x 10(-4)) or the absence of chromosome 11 and 19 trisomy (p=5 x 10(-4)). INTERPRETATION AND
CONCLUSIONS: Our results indicate that distinct types of chromosomal aberrations are closely related to the transcriptional profiles of Delta13-positive cases, suggesting that the contribution of Delta13 to the malignancy should be considered together with associated abnormalities.

Entities:  

Mesh:

Year:  2007        PMID: 17229636     DOI: 10.3324/haematol.10414

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  6 in total

1.  Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myeloma.

Authors:  Julie O'Neal; Feng Gao; Anjum Hassan; Ryan Monahan; Samantha Barrios; Manfred W Kilimann; Ian Lee; Wee J Chng; Ravi Vij; Michael H Tomasson
Journal:  Exp Hematol       Date:  2009-02       Impact factor: 3.084

Review 2.  The molecular characterization and clinical management of multiple myeloma in the post-genome era.

Authors:  Y Zhou; B Barlogie; J D Shaughnessy
Journal:  Leukemia       Date:  2009-08-06       Impact factor: 11.528

3.  Evidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinoma.

Authors:  Federico Colombo; Francesca Baldan; Silvia Mazzucchelli; Ines Martin-Padura; Paola Marighetti; Alessandra Cattaneo; Barbara Foglieni; Marta Spreafico; Silvana Guerneri; Marco Baccarin; Francesco Bertolini; Giorgio Rossi; Vincenzo Mazzaferro; Massimiliano Cadamuro; Marco Maggioni; Luca Agnelli; Paolo Rebulla; Daniele Prati; Laura Porretti
Journal:  PLoS One       Date:  2011-06-23       Impact factor: 3.240

4.  The shaping and functional consequences of the dosage effect landscape in multiple myeloma.

Authors:  Mehmet K Samur; Parantu K Shah; Xujun Wang; Stéphane Minvielle; Florence Magrangeas; Hervé Avet-Loiseau; Nikhil C Munshi; Cheng Li
Journal:  BMC Genomics       Date:  2013-10-02       Impact factor: 3.969

5.  Transcription factor-pathway coexpression analysis reveals cooperation between SP1 and ESR1 on dysregulating cell cycle arrest in non-hyperdiploid multiple myeloma.

Authors:  X Wang; Z Yan; M Fulciniti; Y Li; M Gkotzamanidou; S B Amin; P K Shah; Y Zhang; N C Munshi; C Li
Journal:  Leukemia       Date:  2013-08-08       Impact factor: 11.528

6.  Characterization of the role of Samsn1 loss in multiple myeloma development.

Authors:  Natasha L Friend; Duncan R Hewett; Vasilios Panagopoulos; Jacqueline E Noll; Kate Vandyke; Krzysztof M Mrozik; Stephen Fitter; Andrew C W Zannettino
Journal:  FASEB Bioadv       Date:  2020-08-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.